Rolapitant Hydrochlorid Suppliers & Bulk Manufacturers
Available Forms: Tablets
Available Strengths: 90 mg
Reference Brands: Varubi(USA/LATAM), Varuby(EU)
Category:
Critical Care
Rolapitant Hydrochlorid is available in Tablets
and strengths such as 90 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Rolapitant Hydrochlorid is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Rolapitant Hydrochlorid can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Rolapitant hydrochloride is an orally administered, selective neurokinin-1 (NK1) receptor antagonist with potent antiemetic activity, primarily used to prevent chemotherapy-induced nausea and vomiting (CINV) in adult patients receiving moderately or highly emetogenic cancer therapy. The drug works by competitively binding to NK1 receptors in the central nervous system, thereby blocking the activity of substance P, a key neuropeptide responsible for triggering nausea and vomiting. By inhibiting this pathway, rolapitant helps prevent both acute and delayed emesis associated with cancer chemotherapy.
Rolapitant distinguishes itself from other NK1 receptor antagonists through its rapid onset of action and extended half-life, allowing for effective, long-lasting protection against CINV with a single oral dose. It is typically administered in combination with other antiemetic agents, such as 5-HT3 receptor antagonists and corticosteroids, to maximize patient comfort and adherence to cancer treatment regimens.
As a centrally acting antiemetic, rolapitant provides an important supportive care option for oncology patients, improving quality of life during chemotherapy by reducing the burden of nausea and vomiting and allowing patients to better tolerate their prescribed cancer therapy.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing